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Community-associated methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) has rarely been reported in
the hospital setting. We report an outbreak of 7 cases of
skin and soft tissue infections due to a strain of CA-MRSA.
All patients were admitted to the labor and delivery, nursery,
or maternity units during a 3-week period. Genetic finger-
printing showed that the outbreak strain was closely relat-
ed to the USA 400 strain that includes the midwestern
strain MW2. All isolates contained the staphylococcal chro-
mosome cassette mec type IV. Genes for Panton-Valentine
leukocidin and staphylococcal enterotoxin K were detected
in all isolates, and most contained other enterotoxin genes.
Testing of nearly 2,000 MRSAisolates collected during city-
wide surveillance studies from 1999 to 2003 showed that
≈1% were genetically related to MW2. CA-MRSA strain
MW2 has been present in this region at least since 1999.
This study documents the spread of this strain among
healthy newborns at 1 hospital. 
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
is an established pathogen in most healthcare facili-
ties. Recently, infections due to MRSA have been docu-
mented in children and adults who lack traditional risk
factors (1–4). Most infections caused by these community-
associated (CA) MRSA appear to involve the skin.
However, these strains may occasionally cause pneumonia
or death in previously healthy patients (5,6). In one of the
initial reports of CA-MRSA, 4 deaths were reported in
children infected with a prototypical strain designated
MW2 (5).
Several lines of evidence suggest that the emerging
CA-MRSA isolates are distinct from typical nosocomial
strains (7–9). First, CA-MRSA isolates are generally sus-
ceptible to non-β-lactam antimicrobial agents and genetic
fingerprinting suggests that they are unrelated to hospital-
associated strains (7–9). CA-MRSA isolates possess a
small (21- to 24-kb) and mobile staphylococcal chromo-
some cassette mec type IV (SCCmecIV)–encoding peni-
cillin-binding protein (8). This gene cassette has been
rarely found in contemporary healthcare-associated
MRSA strains. Finally, most of these strains have genes
that encode for multiple virulence factors, including
Panton-Valentine leukocidin (PVL) and superantigens
(5,10). 
Strains of CA-MRSAhave recently caused infections in
hospitalized neonates in the nonoutbreak setting (11). They
have rarely been linked to nosocomial outbreaks. One
report involving postpartum women documented hospital
transmission of the strain MW2 (12). We describe an out-
break in a nursery and maternity unit involving the MW2
strain of CA-MRSA. The prevalence of strains resembling
MW2 in Brooklyn, New York, is also reported.
Materials and Methods
Outbreak Investigation at Hospital A
From October to November 2002, a cluster of skin and
soft tissue infections due to MRSAinvolving pediatric and
maternity patients occurred at a New York City hospital.
The hospital has a labor and delivery unit and 2 units that
house both healthy newborns and maternity patients.
Healthcare workers on these units typically care for
patients on all the units. After the outbreak was recognized,
the following interventions were implemented: 1) nursing
and medical personnel from the involved areas were
informed of the outbreak and potential modes of transmis-
sion of staphylococci, 2) contact precautions were empha-
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tions, 3) alcohol-based hand sanitizers were placed in
involved areas, 4) healthcare workers from involved units
were screened for nasal MRSA colonization, and 5) envi-
ronmental surfaces (including cord clamps, antitheft
transponders, and temperature sensors of baby warmers)
were tested for MRSA contamination. Healthcare workers
colonized with MRSA were treated with intranasal
mupirocin and furloughed until repeat cultures were nega-
tive. To identify any other potential case-patients, letters
concerning the outbreak were sent to pediatricians who
cared for newborns discharged from the affected units dur-
ing the outbreak period. Cases were defined as MRSA
infections in patients who stayed on the labor and delivery,
nursery, or maternity units at any time from October 2002
to December 2002. The medical records of the patients
were reviewed for information regarding prior healthcare
exposures, receipt of antimicrobial agents, underlying
medical conditions, treatment, and clinical outcome. 
Cultures related to the outbreak were grown on tryptic
soy agar plates supplemented with 3% sheep blood;
colonies consistent with S. aureus were identified accord-
ing to standard techniques. All isolates underwent suscep-
tibility testing with the Etest method (AB Biodisk, Solna,
Sweden). Ribotyping was performed with the Riboprinter
Microbial Characterization System (Qualicon,
Wilmington, DE, USA), as previously noted (13). In addi-
tion, isolates of MRSA collected during the outbreak were
fingerprinted by pulsed-field gel electrophoresis (PFGE),
as previously described (13). PFGE results were interpret-
ed according to known criteria (14). 
SCCmec typing was performed by using multiplex
polymerase chain reaction (PCR), under conditions
described by Oliveira et al. (15). Primers to detect the
mecA gene were included as an internal positive control
(15). Multilocus sequence typing (MLST) was performed
on selected isolates as described by Enright et al. (16).
Bidirectional DNA sequencing of 7 amplified housekeep-
ing genes was performed with an automated fluorescent
dye-terminator sequencing system (Applied Biosystems,
Foster City, CA, USA). Allelic types were assigned by
using the MLST database (available from www.mlst.net).
The presence of genetic sequences encoding several
staphylococcal toxins was also investigated for the out-
break isolates. Based on the previously reported distribu-
tion of enterotoxins in CA-MRSA from the United States
(7), the following toxins were selected for investigation:
staphylococcal enterotoxin A(SEA), B (SEB), C (SEC), H
(SEH), and K (SEK). In addition, strains were screened for
PVL and toxic shock syndrome toxin-1 (TSST-1).
Previously published primers and conditions were used to
detect sequences encoding for SEA, SEB, SEC, SEH,
PVL, and TSST-1 (17–19). Genes encoding for SEK were
detected with the following primers: SEK forward: 5′-
TGGATCAATGGAAATCACAAAA-3′ and reverse: 5′-
TTTGGTAGCCCATCATCTCC-3′ (predicted product size
287 bp). The specificity of amplification was verified by
bidirectional sequencing of the product. 
Surveillance Study
The identification of MW2 in the outbreak of the
neonatal-maternity unit prompted a retrospective investi-
gation to determine the regional prevalence of MRSA
resembling this strain. In 1999, 2001, and 2003, surveil-
lance studies were performed in Brooklyn, New York.
Each surveillance study involved collecting all single-
patient isolates of S. aureus from clinical microbiology
laboratories during a 3-month interval. Each study includ-
ed 11–15 hospitals. Susceptibility testing was performed in
the central research laboratory by using the agar dilution
method according to NCCLS methodology (20). All
MRSAisolates were then screened for a phenotype of sus-
ceptibility to clindamycin and ciprofloxacin (typical for
MW2). Isolates possessing this susceptibility pattern
underwent ribotyping and SCCmec typing. The study was
approved by the Institutional Review Board at the State
University of New York (SUNY) Health Science Center
and Maimonides Medical Center.
Results
Outbreak Investigation at Hospital A
From October 18 to November 28, 2002, a total of 8
patients with skin and soft tissue infections due to MRSA
were identified. During this period, 3.5 cases of MRSA
infection occurred each month in the nursery and materni-
ty units. In contrast, no MRSA infections had been report-
ed from the involved units in the 10 months before the
outbreak. Two patients were mothers, and 6 were neonates;
in no instance were both the mother and her child infected.
All had been hospitalized on an involved unit at some
point from October 16 to November 6, 2002. Review of
medical records showed that none of the patients had prior
hospital exposure, underlying chronic medical conditions,
or recent antibiotic therapy.
Clinical manifestations of the infections are included in
Table 1. None of the patients had evidence of infection upon
admission to the hospital. The timing of hospitalization and
onset of clinical symptoms are shown in Figure 1. Patients
stayed on the unit for an average of 5 days (range 2–12
days). Clinical infection developed in 4 of the newborns and
1 mother while in the hospital. Symptoms developed in 2
newborns and 1 mother 2, 10, and 24 days, respectively,
after discharge. β-Lactam antimicrobial agents were initial-
ly administered for 6 patients. Definitive therapy generally
consisted of topical or systemic antimicrobial agents active
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patients had clinical resolution of infection. 
Two additional suspected cases were reported by pedi-
atricians to the Infection Control Department. The first
was in an infant, born in November 2002, who was seen as
an outpatient for pustulosis; however, the site was not cul-
tured. The second case involved another infant, also born
in November 2002, who was readmitted to the hospital 4
days later for treatment of omphalitis. Multiple cultures
yielded no growth. No additional cases were reported from
December10, 2002, to December 31, 2003.
Susceptibility testing showed that all 8 isolates were
susceptible to clindamycin, ciprofloxacin, trimethoprim-
sulfamethoxazole, rifampin, doxycycline, linezolid, and
vancomycin. Of the 8 clinical isolates, 7 (isolates P1-P7)
belonged to 1 ribotype that was identical to the prototypi-
cal MW2 strain (Figure 2). PFGE confirmed that the 7 iso-
lates were identical and closely related to MW2 (Figure 2).
All 7 contained SCCmec type IV. Since the 7 isolates
appeared identical, MLST was performed on one of the
isolates and showed sequence type 1. The PFGE and
MLST pattern are the same as CA-MRSA clone USA 400,
which also includes MW2 (21). Among these 7 isolates, all
contained SEK and PVL, 6 contained SEC and SEH, and
5 contained SEA. None was found to have genes encoding
SEB or TSST-1. The eighth clinical isolate, from a
catheter-site infection, was distinct from the outbreak
strain by ribotyping and PFGE (Figure 2). For this isolate,
SCCmec was nontypable, and MLST typing confirmed a
distinct allelic profile. None of the genes encoding toxins
was detected.
A total of 189 healthcare workers worked on the
involved units during the outbreak period. Screening cul-
tures of the anterior nares were performed in 176 of the
workers in November 2002. Three of the cultures were
positive for MRSA, including 2 from the nursing staff and
1 from a pediatrician. The 3 MRSAstrains possessed a sus-
ceptibility pattern typical for the multidrug-resistant hospi-
tal strains, with resistance to clindamycin and
ciprofloxacin. They belonged to ribotypes distinct from the
outbreak clone, and PFGE confirmed these isolates were
unrelated to MW2 (Figure 2). For the 3 isolates, SCCmec
was nontypable with the multiplex PCR method. None of
the 27 environmental samples collected in November 2002
yielded positive cultures for MRSA.
Surveillance Study
A total of 4,345 isolates of S. aureus were collected in
the 3 surveillance studies conducted in 1999, 2001, and
2003; susceptibility data for these isolates are given in
Table 2. A total of 1,913 (44%) isolates were methicillin-
resistant. Of the 1,913 MRSA isolates, 118 (6%) pos-
sessed the screened phenotype (susceptible to both
clindamycin and fluoroquinolones). Among the 118 iso-
lates, 40 different ribotypes were identified. A total of 11
isolates possessed the same ribotype pattern as the out-
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Figure 1. Time course of hospitalizations and onset of methicillin-
resistant  Stpahylococcus aureus illness during the outbreak at
Hospital A. Solid bars represent period of hospitalization; arrows
represent onset of clinical infection.break clone, MW2. Of the 11 isolates, 4 were known to
come from children. One HIV-infected adult died of over-
whelming sepsis within 24 hours of hospitalization.
Sources of the cultures included skin and soft-tissue in 7
patients, blood/sterile body fluid in 3 patients, and the
genital tract in 1 patient. Nine of the 11 isolates had
SCCmecIV. The number of isolates resembling MW2
remained relatively constant during the 3 surveillances
(4 in 1999, 3 in 2001, and 4 in 2003). 
Discussion
This report characterizes the nosocomial transmission
of the CA-MRSA strain MW2 among healthy newborns
and, possibly, a postpartum woman. Symptoms developed
in 3 patients 2–24 days after hospitalization; 2 may have
acquired the bacteria in the hospital or the community. An
eighth patient, a mother with catheter-site infection, had an
unrelated strain with a pattern suggestive of a hospital-
associated strain. The source of the outbreak and mecha-
nism of transmission were not evident, as no cultures of
staff members or the environment yielded this particular
strain of MRSA. Transmission may have occurred after
MW2 was introduced into the hospital by transient colo-
nization of healthcare workers or by contamination of
shared medical equipment. The infection control measures
enacted in response to the initial cases may have had a role
in controlling the outbreak. Widespread screening of
healthcare workers for MRSA did not detect the outbreak
strain in this and another report (12). While a potential role
for this practice cannot be excluded, current evidence does
not support routinely implementing widespread screening
for CA-MRSA.
In the pediatric population, risk factors associated with
MRSA infections include premature birth or low birth
weight, chronic underlying diseases, prolonged hospital-
ization, invasive or surgical procedures, indwelling
catheters, and prolonged use of antimicrobial agents
(22–25). Outbreaks of S. aureus have been especially chal-
lenging in neonatal nursery units. Prior outbreaks involv-
ing the pandemic strain phage type 80/81 were
characterized by high colonization rates among infants dis-
charged from nurseries and subsequent transmission to
family members (26). In this report, infection developed in
the outpatient setting for 2 patients (following an admis-
sion on the involved unit), which suggests carriage of
MW2 from the hospital back into the community.
Unrecognized CA-MRSA colonization during hospitaliza-
tion could become an additional method of its dissemina-
tion in the community. 
Increased prevalence of CA-MRSA has been reported
in Chicago, Los Angeles, Texas, and Minnesota
(2,3,27,28). In New York City, CA-MRSA appears less
common; 1 investigation reported MRSA carriage in
0.26% of children and their guardians (29). In our present
report, a retrospective analysis of isolates collected from
citywide surveillance studies conducted from 1999 to 2003
suggests that ≈1% of all MRSA isolates in Brooklyn are
genotypically related to the prototypical North American
Methicillin-resistant Staphylococcus aureus
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Figure 2. A) Ribotype and B) pulsed-field gel electrophoresis pat-
terns of 8 clinical isolates of methicillin-resistant Staphylococcus
aureus. Outbreak-related isolates P1–P7 are closely related to
MW2. Clinical isolate P8 and the 3 isolates from healthcare work-
ers (S1–S3) are unrelated to the outbreak strain.CA-MRSA, MW2. Since only MRSA isolates that were
susceptible to both clindamycin and ciprofloxacin were
analyzed, this analysis probably underestimates the true
prevalence. Other strains of CA-MRSA (e.g., USA 300)
and USA 400 strains that acquired resistance to these
antimicrobial agents would have been missed by our
screening methods. 
The introduction of CA-MRSA strains into neonatal
units represents an especially serious challenge. Many of
the infections caused by these strains, including some in
our report, can be unusually severe and life-threatening
(11). Careful vigilance involving surveillance, identifica-
tion of these dangerous strains, and implementation of
infection control measures, should be helpful in prevent-
ing further transmission both within and outside of the
hospital. 
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